Successful treatment of non-IgM lymphoplasmacytic lymphoma by bortezomib-containing regimen: case reports and review of literature

다국어 초록 (Multilingual Abstract)

.

참고문헌 (Reference)

1 Swerdlow SH, "World health organization classification of tumour of hematopoietic and lymphoid tissues" IARC Press 232-235, 2017

2 Naohiro Sekiguchi, "What is the most appropriate regimen for untreated Waldenström macroglobulinemia? - An updated analysis of rituximab and half-dose CHOP therapy and cost effectiveness" 대한혈액학회 54 (54): 153-156, 2019

3 Sekiguchi N, "Successful treatment of immunoglobulin D myeloma by bortezomib and dexamethasone therapy" 50 : 2653-2657, 2011

4 Castillo JJ, "Response and survival for primary therapy combination regimens and maintenance rituximab in Waldenström macroglobulinaemia" 181 : 77-85, 2018

5 Treon SP, "Report from the Sixth International Workshop on Waldenström's Macroglobulinemia" 11 : 69-73, 2011

6 Treon SP, "Primary therapy of Waldenström macroglobulinemia with bortezomib, dexamethasone, and rituximab : WMCTG clinical trial 05-180" 27 : 3830-3835, 2009

7 Itchaki G, "Non-IgM secreting lymphoplasmacytic lymphoma - experience of a reference center for waldenstrom macroglobulinemia" 132 (132): 2886-, 2018

8 Treon SP, "MYD88 L265P somatic mutation in Waldenström's macroglobulinemia" 367 : 826-833, 2012

9 King RL, "Lymphoplasmacytic lymphoma with a non-IgM paraprotein shows clinical and pathologic heterogeneity and may harbor MYD88 L265P mutations" 145 : 843-851, 2016

10 Varettoni M, "Lymphoplasmacytic lymphoma not associated with an IgM monoclonal paraprotein has distinctive clinical and biological features and a similar outcome as compared with Waldenstrom's macroglobulinemia: multicentric study of the rete ematologica lombarda" 130 (130): 4045-, 2017

11 Morel P, "International prognostic scoring system for Waldenstrom macroglobulinemia" 113 : 4163-4170, 2009

12 Sekiguchi N, "Gene expression profile signature of aggressive Waldenström macroglobulinemia with chromosome 6q deletion" 2018 : 6728128-, 2018

13 Owen RG, "Clinicopathological definition of Waldenstrom's macroglobulinemia : consensus panel recommendations from the Second International Workshop on Waldenstrom’s Macroglobulinemia" 30 : 110-115, 2003

14 Cao X, "Clinicopathologic features and outcomes of lymphoplasmacytic lymphoma patients with monoclonal IgG or IgA paraprotein expression" 57 : 1104-1113, 2016

15 강지훈, "Clinical features and survival outcomes of patients with lymphoplasmacytic lymphoma, including non-IgM type, in Korea: a single-center experience" 대한혈액학회 53 (53): 189-197, 2018

16 Olszewski AJ, "Application and outcomes of bendamustine- or bortezomib-based therapy for waldenstrom's macroglobulinemia" 130 (130): 348-, 2017